Background Routine use of whole‐cell pertussis (wP) vaccines was suspended in some
countries in the 1970s and 1980s because of concerns about adverse effects. Following this …

Objective: To assess the efficacy and safety of whole-cell and acellular pertussis vaccines
administered to children singly or within diphtheria, tetanus and pertussis (DTP) vaccines …

The results of phase 3 efficacy trials have shown that acellular and whole-cell pertussis
vaccines can confer protection against whooping cough. However, despite the advances in …

Recent clinical trials have demonstrated that new generation acellular pertussis vaccines
can confer protection against whooping cough. However, the mechanism of protective …

Seven countries in Western Europe collected large, representative serum banks across the
entire age range and tested them for diphtheria anti-toxin (sample size ranged from 2991 to …

High titres of pertussis toxin (PT) antibody have been shown to be predictive of recent
infection with Bordetella pertussis. The seroprevalence of standardized anti-PT antibody …

Cell-mediated immune (CMI) responses to Bordetella pertussis antigens (pertussis toxin
[PT], pertactin [PRN], and filamentous hemagglutinin [FHA]) were assessed in 48-month-old …

Background and Aims To evaluate the National Immunisation Programme (NIP) a
population-based cross-sectional seroepidemiological study was performed in the …

Immunization with acellular pertussis vaccine (aP) induces higher specific antibody levels
and fewer adverse reactions than does immunization with the whole-cell vaccine (wP) …

The evidence from pre-licensure studies does not suggest that there are clinically important
differences in reactogenicity between acellular vaccines. The merits of different acellular …